Signaturefd LLC Sells 62 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Signaturefd LLC cut its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.3% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,370 shares of the company’s stock after selling 62 shares during the period. Signaturefd LLC’s holdings in IDEXX Laboratories were worth $692,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Riverview Trust Co purchased a new stake in IDEXX Laboratories in the 1st quarter worth $26,000. OneAscent Wealth Management LLC bought a new position in shares of IDEXX Laboratories in the first quarter worth about $206,000. Vicus Capital purchased a new stake in shares of IDEXX Laboratories during the first quarter worth about $210,000. Aviance Capital Partners LLC bought a new stake in IDEXX Laboratories during the 1st quarter valued at approximately $405,000. Finally, Oak Thistle LLC purchased a new position in IDEXX Laboratories in the 1st quarter worth approximately $297,000. Institutional investors own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on IDXX. Piper Sandler dropped their target price on shares of IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating for the company in a research report on Wednesday, August 14th. StockNews.com downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, July 10th. JPMorgan Chase & Co. reduced their target price on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Stifel Nicolaus dropped their price target on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a research note on Thursday, October 10th. Finally, BTIG Research started coverage on IDEXX Laboratories in a research note on Thursday, July 25th. They issued a “buy” rating and a $580.00 price objective on the stock. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $574.13.

IDEXX Laboratories Stock Down 1.2 %

NASDAQ:IDXX opened at $452.27 on Friday. The company’s 50 day moving average is $486.11 and its two-hundred day moving average is $490.23. The company has a market cap of $37.35 billion, a PE ratio of 43.78, a P/E/G ratio of 4.14 and a beta of 1.33. IDEXX Laboratories, Inc. has a twelve month low of $372.50 and a twelve month high of $583.39. The company has a current ratio of 1.37, a quick ratio of 1.03 and a debt-to-equity ratio of 0.33.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $2.44 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.88 by ($0.44). IDEXX Laboratories had a net margin of 22.34% and a return on equity of 57.03%. The company had revenue of $1 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same period last year, the firm earned $2.67 EPS. The business’s quarterly revenue was up 6.4% compared to the same quarter last year. Analysts anticipate that IDEXX Laboratories, Inc. will post 10.44 EPS for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.